Fact Sheets
Resources
Filter by:
Or browse by
popular tag:
Fact Sheets
Para & Phaeo Factsheet
Wellness
Parenting through Cancer
Clinical Trials
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET)
PARLuNET is a phase 1 dose-escalation study designed to evaluate the safety and tolerability of talazoparib (PARP Inhibitor) in...
Other Resources
Patient Card – Bathroom
Other Resources
Patient Card – Carcinoid Crisis Medical Alert
Educational Videos, Explainer Videos
Peptide receptor radionuclide therapy (PRRT)
Forum Videos
Perth NET Patient Forum 2023
Clinical Trials
Phase 3 Trial of CAM2029 vs Standard Treatments in GEP-NET Patients
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET.
Causes & Risk Factors
Potential Carcinogens and Neuroendocrine Tumour Risk
Wellness
Preparing for the holiday season
Wellness
Problem-Solving during a Neuroendocrine Cancer Diagnosis
Prognosis
Prognosis in Rare and Aggressive Neuroendocrine Cancers
Prognosis
Prognostic Significance of Tumour Grade in NETs
Fact Sheets
PRRT
Treatment Options
